Abstract | OBJECTIVE: METHODS:
Diltiazem, 240-480 mg/day, was given to 4 patients with idiopathic or CREST-related ( calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias) calcinosis for 1-12 years. Serial radiographs of the affected areas, using identical technique, and clinical evaluations were obtained. A fifth patient, who did not tolerate diltiazem, received verapamil, 120 mg/day for 18 months. RESULTS: All patients taking diltiazem had a reduction or disappearance of the calcific lesions, with striking clinical improvement. One patient's case was followed for 12 years. The response to diltiazem during the first 5 years of treatment has been previously reported in detail; however, over 7 years of additional treatment, there was further reduction of the lesions. One patient developed a large calcific lesion while receiving verapamil for hypertension, and after verapamil was replaced with diltiazem, there was a dramatic response. Verapamil was ineffective in the fifth patient, who did not tolerate diltiazem. CONCLUSION:
|
Authors | G M Palmieri, J I Sebes, J A Aelion, M Moinuddin, M W Ray, G C Wood, M R Leventhal |
Journal | Arthritis and rheumatism
(Arthritis Rheum)
Vol. 38
Issue 11
Pg. 1646-54
(Nov 1995)
ISSN: 0004-3591 [Print] United States |
PMID | 7488286
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Calcium Channel Blockers
- Diltiazem
|
Topics |
- Adult
- Aged
- Calcinosis
(drug therapy, etiology)
- Calcium Channel Blockers
(therapeutic use)
- Diltiazem
(therapeutic use)
- Female
- Follow-Up Studies
- Humans
|